LOS ANGELES, Oct. 11 /PRNewswire/ -- ImaginAb, Inc. and Imanet (part of GE Healthcare) have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.
"ImaginAb is pleased to have formalized this agreement with Imanet", said Dr. Christian Behrenbruch, CEO of ImaginAb. "Imanet's superb network of pre-clinical and clinical imaging sites and leveraging GE's expertise in radiochemistry will be invaluable for both our internal product pipeline as well as for ImaginAb's pharmaceutical partnerships. We also intend to work with Imanet to validate our library of pre-clinical imaging probes for microPET and microSPECT imaging".
Molecular imaging using recombinant antibody fragments has emerged over the last decade as a flexible research platform for targeting diagnostic and prognostic biomarkers potentially beneficial for the development of molecular therapies by the biopharmaceutical industry. ImaginAb's recombinant antibody fragments enable development of tailored, highly specific imaging agents for drug research. ImaginAb's imaging agent development will benefit from Imanet's PET infrastructure, know-how and nearly 10 years in conducting PET studies with high sensitivity and image resolution for drug development.
Dr. Eric Agdeppa, Imaging Solutions Manager of Imanet, commented, "ImaginAb's technology shows tremendous potential to address a wide range of unmet needs in clinical imaging. ImaginAb has an extensive pipeline of new products that we are pleased to help develop. We also see synergy between Imanet's capabilities and ImaginAb's rapidly growing pharmaceutical industry clientele."
Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.
About GE Imanet
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. The company's broad expertise in medical imaging and information technologies, medical diagnostics, drug discovery and performance solutions services help its customers to deliver better care to more people around the world at a lower cost. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professional and their patients in more than 100 countries. An integral part of GE Healthcare's Medical Diagnostics business, Imanet™ is a network of clinical PET centers conducting exploratory phase PET imaging studies to aid in the development of products for the pharmaceutical industry since 2001. For more information about GE Healthcare, visit www.gehealthcare.com and www.imanet.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Dr. Anna Wu
|SOURCE ImaginAb, Inc.|
Copyright©2010 PR Newswire.
All rights reserved